Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

Merck's blockbuster drug Keytruda is facing a patent cliff, prompting the pharmaceutical industry to explore next-generation cancer treatments. These new approaches include antibody-drug conjugates (ADCs) and bispecific antibodies, with several major pharmaceutical companies actively developing and testing these innovations.